At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come. Join Roche, where every voice matters.
The PositionAI Biology & Translation (AIBT) develops and applies state-of-the-art artificial intelligence to accelerate biomedical discovery across Research and Early Development in Genentech & Roche. We combine advances in foundation models, multimodal machine learning, and large-scale biological data to advance target discovery, disease understanding, biomarker development, and translational science.
We are seeking a (Senior) ML Scientist with deep expertise in modern machine learning to lead the development and application of next-generation AI technologies for designing DNA and RNA sequences for nucleic acid-based medicines. We work closely with stakeholders in Cell Therapy, Gene Therapy, and Vaccine Oncology on diverse projects, ranging from platform development for lab-in-the-loop refinement of sequence designs to lead optimization for portfolio projects. Representative work includes designing regulatory elements to confer cell-type-specific transcription and engineering synonymous coding sequences to enhance translational efficiency.
As a Scientist / Senior Scientist, you will directly lead sequence design campaigns, translating biological questions into predictive and generative models, and driving iterative sequence optimization in close collaboration with wet-lab experimentalists.
The Opportunity
- Build, train, and fine-tune machine learning algorithms to optimize nucleic acid-based medicines for active portfolio projects
- Design candidate sequence libraries for lab-in-the-loop optimization cycles, analyze experimental readouts (e.g., MPRA, NGS), and iteratively update designs
- Collaborate cross-functionally with wet-lab scientists and project leads to understand therapeutic constraints and tailor design algorithms accordingly
- Present technical findings, candidate designs, and model performance metrics to cross-functional team members and stakeholders
- Stay current with advancements in biological sequence modeling and nucleic acid therapeutics to bring state-of-the-art methods into our pipeline
- Contribute to scientific publications
Who You Are
- Ph.D. in a quantitative discipline (Bioinformatics, Computational Biology, Computer Science, Machine learning, or a related field) with 0-4 years of post-doctoral or industry experience
- Demonstrated research impact at the interface of machine learning and molecular biology, evidenced by publications in top-tier journals or ML conferences
- Strong Python programming skills and proficiency in deep learning frameworks such as PyTorch
- Hands-on experience developing, training, or fine-tuning sequence-to-function models for biological molecules (preferably DNA/RNA)
- Excellent communication skills in English, with the ability to speak to both computational and experimental scientists
Preferred Qualifications
- Prior experience applying machine learning in a biotech, pharma, or industry setting
- Domain knowledge in nucleic acid-based therapeutics (e.g., mRNA design, AAV capsid/promoter engineering, cell therapy vectors)
- Experience with advanced ML frameworks relevant to sequence design, such as generative modeling (diffusion, autoregressive sequence models, masked language models), active learning, model interpretability, or uncertainty quantification
- Familiarity with high-throughput functional genomics data processing (e.g., MPRA, RNA-seq, ribosome profiling)
About AI Biology & Translation (AIBT)
AI Biology & Translation (AIBT) is part of the Computational Sciences Center of Excellence (CS-CoE). AIBT advances the development and application of cutting-edge artificial intelligence to accelerate biomedical discovery and translational science. By integrating expertise in machine learning, computational biology, and software engineering, AIBT develops AI capabilities that enable researchers to generate new biological insights, accelerate scientific decision-making, and transform research across Genentech & Roche.
Who we are
A healthier future drives us to innovate. Together, more than 100’000 employees across the globe are dedicated to advance science, ensuring everyone has access to healthcare today and for generations to come. Our efforts result in more than 26 million people treated with our medicines and over 30 billion tests conducted using our Diagnostics products. We empower each other to explore new possibilities, foster creativity, and keep our ambitions high, so we can deliver life-changing healthcare solutions that make a global impact.
Let’s build a healthier future, together.
Roche is an Equal Opportunity Employer.
Skills Required
- Ph.D. in bioinformatics, computational biology, computer science, machine learning, or a related quantitative discipline
- 0–4 years of post-doctoral or industry experience
- Research impact at the interface of machine learning and molecular biology, demonstrated through publications in top-tier journals or ML conferences
- Strong Python programming skills
- Proficiency with deep learning frameworks such as PyTorch
- Hands-on experience developing, training, or fine-tuning sequence-to-function models for biological molecules, preferably DNA or RNA
- Excellent English communication skills with computational and experimental scientists
- Machine learning experience in a biotech, pharma, or industry setting
- Domain knowledge in nucleic acid-based therapeutics, such as mRNA design, AAV engineering, or cell therapy vectors
- Experience with generative modeling, active learning, model interpretability, or uncertainty quantification
- Familiarity with high-throughput functional genomics data processing, including MPRA, RNA-seq, or ribosome profiling
Roche Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Roche and has not been reviewed or approved by Roche.
-
Retirement Support — U.S. materials describe a 401(k) with both matching and an additional company contribution, supported by formal plan documents and true‑up features. This structure is positioned as a standout element of the total package, particularly at Genentech.
-
Leave & Time Off Breadth — Time‑off provisions include substantial vacation, a year‑end shutdown, and a paid six‑week sabbatical after six years. These elements indicate a recharge‑oriented approach within the U.S. offering.
-
Healthcare Strength — Company materials emphasize comprehensive medical, dental, vision, and mental‑health resources alongside well‑being programs. Benefits pages consistently highlight breadth across core health coverage elements.
Roche Insights
What We Do
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI).







